Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain
Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain: Multicenter, Open Label, Prospective, Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who complain of spinal disorder-related chronic pain persisting for 3 months or longer
- Patients who can fully observe the overall clinical study requirements including K-ODI completion at the investigator's discretion
- Patients who complain of severe pain (NRS score = 7) because pain was not treated enough with the previous analgesic
- Patients who have never been administered fentanyl matrix over the last one month
Exclusion Criteria:
- Patients with a history of the drug or alcohol abuse in the past or now
- Childbearing women who are pregnant or likely to be pregnant during the study period and male patients who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception (implant, injections, oral contraceptives, intrauterine device, etc.)
- Patients who are unable to use a transdermal system due to skin disease
- Patients with serious mental disorder
- Patients with history of hypersensitivity to opioid analgesics
- Patients with history of CO2 retention
- Patients who are not eligible for the study participation based on warnings, precautions and contra medications in the package insert of the study drug at the investigator's discretion
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
001
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
|
002
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
|
003
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
|
004
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
|
005
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
|
006
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
|
007
|
Infection, starting with 12mcg/h (flexible dose)
(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
Bone Fracture, starting with 12mcg/h (flexible dose)
(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
Other Deformity, starting with 12mcg/h (flexible dose)
(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pain intensity with Numeric Rating Scale
Time Frame: baseline, week 4 and week 8
|
baseline, week 4 and week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Impact of activity of daily living and social activities
Time Frame: baseline, week 4 and week 8
|
baseline, week 4 and week 8
|
|
Investigator and patient global assessment
Time Frame: baseline, week 4 and week 8
|
baseline, week 4 and week 8
|
|
CGI-I (Clinical Global Impression)
Time Frame: baseline, week 4 and week 8
|
baseline, week 4 and week 8
|
|
K-ODI (Korean version of Oswestry Disability Index)
Time Frame: baseline, week 4 and week 8
|
baseline, week 4 and week 8
|
|
Improvement of sleep disturbance
Time Frame: baseline, week 4 and week 8
|
baseline, week 4 and week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Bone Diseases
- Back Pain
- Low Back Pain
- Spinal Diseases
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
Other Study ID Numbers
Other Study ID Numbers
- CR015409
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.